Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Cardiovascular Imaging Reports
Erschienen in: Current Cardiovascular Imaging Reports 10/2015

01.10.2015 | Cardiac Magnetic Resonance (E Nagel and V Puntmann, Section Editors)

Imaging in Deciphering Histological Substrates in Hypertrophic Cardiomyopathy

verfasst von: Raquel Sukhbir, Rabah Alreshq, Nicholas Child

Erschienen in: Current Cardiovascular Imaging Reports | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Over the last 5 years, there has been great interest in how advanced imaging can be used in hypertrophic cardiomyopathy (HCM) to better understand the disease and improve patient diagnosis, monitoring and outcomes. The role of imaging has progressed beyond its initial purpose of simply identifying hypertrophic regions of myocardium, and now has the potential for in vivo tissue characterization reflecting the pathological histological underlying changes. This article aims to review the recent developments in advanced imaging and their potential clinical implications in HCM. The majority of these developments have occurred in the field of cardiac magnetic resonance (CMR) imaging, which is reflected in CMR forming a large proportion of the article, with other non-CMR techniques discussed in relation to these findings. Realizing the histological progression of HCM through advanced imaging has the potential to revolutionize diagnosis, management and future treatment.
Literatur
1.
Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J. 2003;24:1965–91.PubMedCrossRef
2.
Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med. 2011;364:1643–56.PubMedCrossRef
3.
4.
Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785–9.PubMedCrossRef
5.
Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.PubMedCrossRef
6.
Olivotto I, Cecchi F, Poggesi C, et al. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circulat Heart Fail. 2012;5:535–46.CrossRef
7.
Maron BJ, Ommen SR, Semsarian C, et al. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64:83–99.PubMedCrossRef
8.
Bogun FM, Desjardins B, Good E, et al. Delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy: utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol. 2009;53:1138–45.PubMedCentralPubMedCrossRef
9.••
Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004;363:1881–91. Important overview of HCM. PubMedCrossRef
10.
11.
Olivotto I, d’Amati G, Basso C, et al. Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. Cardiovasc Res. 2015;105:409–23.PubMedCrossRef
12.
Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112:855–61.PubMedCrossRef
13.
Hasenfuss G. Sarcomeric cardiomyopathies: from bedside to bench and back. Cardiovasc Res. 2015;105:395–6.PubMedCrossRef
14.
Pattanayak P, Bleumke DA. Tissue characterization of the myocardium: state of the art characterization by magnetic resonance and computed tomography imaging. Radiol Clin North Am. 2015;53:413–23.PubMedCrossRef
15.
Shirani J, Pick R, Roberts WC, et al. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000;35:36–44.PubMedCrossRef
16.
Ho CY, Lopez B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010;363:552–63.PubMedCentralPubMedCrossRef
17.
Basso C, Thiene G, Corrado D, et al. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol. 2000;31:988–98.PubMedCrossRef
18.
Croisille P, Revel D, Saeed M. Contrast agents and cardiac MR imaging of myocardial ischemia: from bench to bedside. Eur Radiol. 2006;16:1951–63.PubMedCrossRef
19.
Wesbey GE, Higgins CB, McNamara MT, et al. Effect of gadolinium-DTPA on the magnetic relaxation times of normal and infarcted myocardium. Radiology. 1984;153:165–9.PubMedCrossRef
20.
Lehrke S, Lossnitzer D, Schob M, et al. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart. 2011;97:727–32.PubMedCrossRef
21.
Yokota H, Imai Y, Tsuboko Y, et al. Nocturnal blood pressure pattern affects left ventricular remodeling and late gadolinium enhancement in patients with hypertension and left ventricular hypertrophy. PLoS One. 2013;8:e67825.PubMedCentralPubMedCrossRef
22.
Nagai T, Kohsaka S, Okuda S, et al. Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest. 2014;146:1064–72.PubMedCrossRef
23.
Radunski UK, Lund GK, Stehning C, et al. CMR in patients with severe myocarditis: diagnostic value of quantitative tissue markers including extracellular volume imaging. J Am Coll Cardiol Img. 2014;7:667–75.CrossRef
24.
Kwon DH, Smedira NG, Rodriguez ER, et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol. 2009;54:242–9.PubMedCrossRef
25.
Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218:215–23.PubMedCrossRef
26.
Moravsky G, Ofek E, Rakowski H, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. J Am Coll Cardiol Img. 2013;6:587–96.CrossRef
27.
Funada A, Kanzaki H, Noguchi T, et al. Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction. Heart Vessels 2015.
28.
Appelbaum E, Maron BJ, Adabag S, et al. Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. Circulat Cardiovasc Imag. 2012;5:78–85.CrossRef
29.
Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40:2156–64.PubMedCrossRef
30.
Teraoka K, Hirano M, Ookubo H, et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging. 2004;22:155–61.PubMedCrossRef
31.
Kwon DH, Setser RM, Popovic ZB, et al. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Int J Cardiovasc Imag. 2008;24:617–25.CrossRef
32.
Moon JC, McKenna WJ, McCrohon JA, et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561–7.PubMedCrossRef
33.
O’Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867–74.PubMedCrossRef
34.
Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:875–87.PubMedCrossRef
35.
Maron MS, Appelbaum E, Harrigan CJ, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circulat Heart Fail. 2008;1:184–91.CrossRef
36.••
Green JJ, Berger JS, Kramer CM, et al. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. J Am Coll Cardiol Img. 2012;5:370–7. Important LGE meta-analysis. CrossRef
37.
Rubinshtein R, Glockner JF, Ommen SR, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circulat Heart Fail. 2010;3:51–8.CrossRef
38.
Hen Y, Iguchi N, Utanohara Y, et al. Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging in Japanese hypertrophic cardiomyopathy patients. Circulat J : Off J Jap Circulat Soc. 2014;78:929–37.CrossRef
39.
Hanneman K, Crean AM, Williams L, et al. Cardiac magnetic resonance imaging findings predict major adverse events in apical hypertrophic cardiomyopathy. J Thorac Imaging. 2014;29:331–9.PubMedCrossRef
40.••
Dawson DK, Hawlisch K, Prescott G, et al. Prognostic role of CMR in patients presenting with ventricular arrhythmias. J Am Coll Cardiol Img. 2013;6:335–44. Important LGE risk analysis. CrossRef
41.
Chan W, Duffy SJ, White DA, et al. Acute left ventricular remodeling following myocardial infarction: coupling of regional healing with remote extracellular matrix expansion. J Am Coll Cardiol Img. 2012;5:884–93.CrossRef
42.
Prinz C, Schwarz M, Ilic I, et al. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy. Can J Cardiol. 2013;29:358–63.PubMedCrossRef
43.
Kwon DH, Halley CM, Carrigan TP, et al. Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. J Am Coll Cardiol Img. 2009;2:34–44.CrossRef
44.
Fujita T, Konno T, Yokawa J, et al. Increased extent of myocardial fibrosis in genotyped hypertrophic cardiomyopathy with ventricular tachyarrhythmias. J Cardiol 2014.
45.
Sakamoto N, Sato N, Oikawa K, et al. Late gadolinium enhancement of cardiac magnetic resonance imaging indicates abnormalities of time-domain T-wave alternans in hypertrophic cardiomyopathy with ventricular tachycardia. Heart Rhythm : Off J Heart Rhythm Society 2015.
46.••
Sakamoto N, Kawamura Y, Sato N, et al. Late gadolinium enhancement on cardiac magnetic resonance represents the depolarizing and repolarizing electrically damaged foci causing malignant ventricular arrhythmia in hypertrophic cardiomyopathy. Heart rhythm : Off J Heart Rhythm Soc. 2015;12:1276–84. Important and recent relationship between LGE and endocardial scar and location of arrhythmias. CrossRef
47.
Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130:484–95.PubMedCrossRef
48.
Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58:e212–60.PubMedCrossRef
49.
Choi HM, Kim KH, Lee JM, et al. Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy. Heart. 2015;101:870–6.PubMedCrossRef
50.
Shimada YJ, Passeri JJ, Baggish AL, et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2013;1:480–7.PubMedCentralPubMedCrossRef
51.
Lardo AC, Cordeiro MA, Silva C, et al. Contrast-enhanced multidetector computed tomography viability imaging after myocardial infarction: characterization of myocyte death, microvascular obstruction, and chronic scar. Circulation. 2006;113:394–404.PubMedCentralPubMedCrossRef
52.
Bettencourt N, Ferreira ND, Leite D, et al. CAD detection in patients with intermediate-high pre-test probability: low-dose CT delayed enhancement detects ischemic myocardial scar with moderate accuracy but does not improve performance of a stress-rest CT perfusion protocol. J Am Coll Cardiol Img. 2013;6:1062–71.CrossRef
53.
Lessick J, Abadi S, Agmon Y, et al. Multidetector computed tomography predictors of late ventricular remodeling and function after acute myocardial infarction. Eur J Radiol. 2012;81:2648–57.PubMedCrossRef
54.
Shiozaki AA, Santos TS, Artega E, et al. Images in cardiovascular medicine. Myocardial delayed enhancement by computed tomography in hypertrophic cardiomyopathy. Circulation. 2007;115:e430–1.PubMedCrossRef
55.
Berliner JI, Kino A, Carr JC, et al. Cardiac computed tomographic imaging to evaluate myocardial scarring/fibrosis in patients with hypertrophic cardiomyopathy: a comparison with cardiac magnetic resonance imaging. Int J Cardiovasc Imag. 2013;29:191–7.CrossRef
56.
Langer C, Lutz M, Eden M, et al. Hypertrophic cardiomyopathy in cardiac CT: a validation study on the detection of intramyocardial fibrosis in consecutive patients. Int J Cardiovasc Imag. 2014;30:659–67.CrossRef
57.
Shiozaki AA, Senra T, Arteaga E, et al. Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. J Cardiovasc Comput Tomograp. 2013;7:173–81.CrossRef
58.
Serri K, Reant P, Lafitte M, et al. Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2006;47:1175–81.PubMedCrossRef
59.
Popovic ZB, Kwon DH, Mishra M, et al. Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyperenhancement magnetic resonance imaging. J Am Soc Echocardiogr. 2008;21:1299–305.PubMedCrossRef
60.
Saito M, Okayama H, Yoshii T, et al. Clinical significance of global two-dimensional strain as a surrogate parameter of myocardial fibrosis and cardiac events in patients with hypertrophic cardiomyopathy. Europ Heart J Cardiovasc Imag. 2012;13:617–23.CrossRef
61.
Di Salvo G, Pacileo G, Limongelli G, et al. Non sustained ventricular tachycardia in hypertrophic cardiomyopathy and new ultrasonic derived parameters. J Am Soc Echocardiogr. 2010;23:581–90.PubMedCrossRef
62.
Amano Y, Kumita S, Takayama M, et al. Comparison of contrast-enhanced MRI with iodine-123 BMIPP for detection of myocardial damage in hypertrophic cardiomyopathy. AJR Am J Roentgenol. 2005;185:312–8.PubMedCrossRef
63.
Kuusisto J, Karja V, Sipola P, et al. Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart. 2012;98:1007–13.PubMedCentralPubMedCrossRef
64.
Abdel-Aty H, Cocker M, Strohm O, et al. Abnormalities in T2-weighted cardiovascular magnetic resonance images of hypertrophic cardiomyopathy: regional distribution and relation to late gadolinium enhancement and severity of hypertrophy. J Magn Reson Imaging. 2008;28:242–5.PubMedCrossRef
65.
Hen Y, Iguchi N, Machida H, et al. High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy. Heart Vessel. 2013;28:742–9.CrossRef
66.
Todiere G, Pisciella L, Barison A, et al. Abnormal T2-STIR magnetic resonance in hypertrophic cardiomyopathy: a marker of advanced disease and electrical myocardial instability. PLoS One. 2014;9:e111366.PubMedCentralPubMedCrossRef
67.
Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849–65.PubMedCrossRef
68.
Bhuva AN, Treibel TA, Fontana M, et al. T1 mapping: non-invasive evaluation of myocardial tissue composition by cardiovascular magnetic resonance. Expert Rev Cardiovasc Ther. 2014;12:1455–64.PubMedCrossRef
69.
Caspari PG, Gibson K, Harris P. Changes in myocardial collagen in normal development and after beta blockade. Rec Adv Stud Cardiac Struct Metab. 1975;7:99–104.
70.
Fang L, Beale A, Ellims AH, et al. Associations between fibrocytes and postcontrast myocardial T1 times in hypertrophic cardiomyopathy. J Am Heart Assoc. 2013;2:e000270.PubMedCentralPubMedCrossRef
71.
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709–17.PubMedCrossRef
72.
Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investig Circulat. 2000;102:2700–6.CrossRef
73.
Nagel E, Narula J. Evolution and revolution in CMR imaging. J Am Coll Cardiol Img. 2013;6:837–8.CrossRef
74.
Treibel TA, White SK, Moon JC. Myocardial tissue characterization: histological and pathophysiological correlation. Curr Cardiovasc Imag Rep. 2014;7:9254.CrossRef
75.••
Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magnet Resonance : Off J Soc Cardiovasc Magnet Resonance. 2013;15:92. Overview of the use of T1 mapping. CrossRef
76.
Liu S, Han J, Nacif MS, et al. Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials. J Cardiovasc Magnet Resonance : Off J Soc Cardiovasc Magnet Resonance. 2012;14:90.CrossRef
77.
Hwang SH, Advanced CBW, Cardiac MR. Imaging for myocardial characterization and quantification: T1 mapping. Korean Circulat J. 2013;43:1–6.CrossRef
78.••
Rogers T, Dabir D, Mahmoud I, et al. Standardization of T1 measurements with MOLLI in differentiation between health and disease--the ConSept study. J Cardiovasc Magnet Resonance : Off J Soc Cardiovasc Magnet Resonance. 2013;15:78. The use of clinical T1 mapping. CrossRef
79.
Messroghli DR, Radjenovic A, Kozerke S, et al. Modified look-locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med. 2004;52:141–6.PubMedCrossRef
80.
Piechnik SK, Ferreira VM, Dall’Armellina E, et al. Shortened modified look-locker inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magnet Resonance : Off J Soc Cardiovasc Magnet Resonance. 2010;12:69.CrossRef
81.
DM H, JC M. Review of T1 mapping methods: comparative effectiveness including reproducibility issues. Curr Cardiovasc Imag Rep. 2014;7:9252.CrossRef
82.
Dabir D, Child N, Kalra A. Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study. J Cardiovasc Magnet Resonance : Off J Soc Cardiovasc Magnet Resonance. 2014;16:69.CrossRef
83.
Messroghli DR, Greiser A, Frohlich M, et al. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging. 2007;26:1081–6.PubMedCrossRef
84.
Kehr E, Sono M, Chugh SS, et al. Gadolinium-enhanced magnetic resonance imaging for detection and quantification of fibrosis in human myocardium in vitro. Int J Cardiovasc Imag. 2008;24:61–8.CrossRef
85.
Messroghli DR, Niendorf T, Schulz-Menger J, et al. T1 mapping in patients with acute myocardial infarction. J Cardiovasc Magnet Resonance : Off J Soc Cardiovasc Magnet Resonance. 2003;5:353–9.CrossRef
86.••
Puntmann VO, Voigt T, Chen Z, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. J Am Coll Cardiol Img. 2013;6:475–84. The use of T1 in HCM. CrossRef
87.
Wong TC, Piehler K, Meier CG, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012;126:1206–16.PubMedCentralPubMedCrossRef
88.
Dass S, Suttie JJ, Piechnik SK, et al. Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy. Circulat Cardiovasc Imag. 2012;5:726–33.CrossRef
89.
Kachenoura N, Besson-Hajji L, Graves MJ, et al. Kinetic index combining native and postcontrast myocardial T1 in hypertrophic cardiomyopathy. J Magn Reson Imaging 2015.
90.
Ellims AH, Iles LM, Ling LH, et al. A comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac magnetic resonance imaging: linking genotype with fibrotic phenotype. Europ Heart J Cardiovasc Imag. 2014;15:1108–16.CrossRef
91.
Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122:138–44.PubMedCrossRef
92.
Ho CY, Abbasi SA, Neilan TG, et al. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circulat Cardiovasc Imag. 2013;6:415–22.CrossRef
93.
Malek LA, Werys K, Klopotowski M, et al. Native T1-mapping for non-contrast assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy—comparison with late enhancement quantification. Magn Reson Imaging. 2015;33:718–24.PubMedCrossRef
94.
Wang C, Zheng J, Sun J, et al. Endogenous contrast T1rho cardiac magnetic resonance for myocardial fibrosis in hypertrophic cardiomyopathy patients. J Cardiol 2015.
95.
Nacif MS, Kawel N, Lee JJ, et al. Interstitial myocardial fibrosis assessed as extracellular volume fraction with low-radiation-dose cardiac CT. Radiology. 2012;264:876–83.PubMedCentralPubMedCrossRef
96.
Bandula S, White SK, Flett AS, et al. Measurement of myocardial extracellular volume fraction by using equilibrium contrast-enhanced CT: validation against histologic findings. Radiology. 2013;269:396–403.PubMedCrossRef
97.
Almaas VM, Haugaa KH, Strom EH, et al. Increased amount of interstitial fibrosis predicts ventricular arrhythmias, and is associated with reduced myocardial septal function in patients with obstructive hypertrophic cardiomyopathy. Europace : European Pacing, Arrhythmias, Cardiac Electrophysiol: J Work Group Cardiac Pacing, arrhythmias, Cardiac Cell Electrophysiol Europ Soc Cardiol. 2013;15:1319–27.CrossRef
98.
Correia E, Rodrigues B, Santos LF, et al. Longitudinal left ventricular strain in hypertrophic cardiomyopathy: correlation with nonsustained ventricular tachycardia. Echocardiography. 2011;28:709–14.PubMedCrossRef
99.
Zhang YD, Li M, Qi L, et al. Hypertrophic cardiomyopathy: cardiac structural and microvascular abnormalities as evaluated with multi-parametric MRI. Eur J Radiol 2015.
100.
Timmer SA, Knaapen P. Coronary microvascular function, myocardial metabolism, and energetics in hypertrophic cardiomyopathy: insights from positron emission tomography. Europ Heart J Cardiovasc Imag. 2013;14:95–101.CrossRef
101.
Olivotto I, Cecchi F, Gistri R, et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2006;47:1043–8.PubMedCrossRef
102.
Cecchi F, Olivotto I, Gistri R, et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349:1027–35.PubMedCrossRef
103.
104.
105.
Child N, Muhr T, Sammut E, et al. Prevalence of myocardial crypts in a large retrospective cohort study by cardiovascular magnetic resonance. J Cardiovasc Magnet Resonance : Off J Soc Cardiovasc Magnet Resonance. 2014;16:66.CrossRef
106.
Erol C, Koplay M, Olcay A, et al. Congenital left ventricular wall abnormalities in adults detected by gated cardiac multidetector computed tomography: clefts, aneurysms, diverticula and terminology problems. Eur J Radiol 2012.
107.
Johansson B, Maceira AM, Babu-Narayan SV, et al. Clefts can be seen in the basal inferior wall of the left ventricle and the interventricular septum in healthy volunteers as well as patients by cardiovascular magnetic resonance. J Am Coll Cardiol. 2007;50:1294–5.PubMedCrossRef
108.
Petryka J, Baksi AJ, Prasad SK, et al. Prevalence of inferobasal myocardial crypts among patients referred for cardiovascular magnetic resonance. Circulat Cardiovasc Imag. 2014;7:259–64.CrossRef
109.
Germans T, Wilde AA, Dijkmans PA, et al. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol. 2006;48:2518–23.PubMedCrossRef
110.
Brouwer WP, Germans T, Head MC, et al. Multiple myocardial crypts on modified long-axis view are a specific finding in pre-hypertrophic HCM mutation carriers. Europ Heart J Cardiovasc Imag. 2012;13:292–7.CrossRef
111.
Maron MS, Rowin EJ, Lin D, et al. Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circulat Cardiovasc Imag 2012.
Metadaten
Titel
Imaging in Deciphering Histological Substrates in Hypertrophic Cardiomyopathy
verfasst von
Raquel Sukhbir
Rabah Alreshq
Nicholas Child
Publikationsdatum
01.10.2015
Verlag
Springer US
Erschienen in
Current Cardiovascular Imaging Reports / Ausgabe 10/2015
Print ISSN: 1941-9066
Elektronische ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-015-9355-8

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise